SYF3ed2b59c4d644f9698075ef4355e9af4Registry ID: 2026-527107-22-00|RecruitingPhase 4
AUC-targeted tacrolimus dosing in kidney transplant recipients
ACTOR – AUC Control of Tacrolimus in Organ Recipients
Loading search results
ACTOR – AUC Control of Tacrolimus in Organ Recipients
interventional
N/A
1 country
1
To investigate whether AUC-guided tacrolimus dosing results in a greater proportion of patients achieving individualized therapeutic AUC0-12 targets 8 weeks after transplantation compared to standard C0-guided dosing
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 10, 2026
Actual (reported)AUC0-12 (rich sampled)
AUC0-12 (limited sampling, 3 points)
intra-individual coefficient of variation (CV%) of the AUC0-12/C0 ratio
microbiome metagenomics
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Formulated product
PROGRAF 1 mg capsule
The registry describes a specific formulation. Its exact chemical ingredients and approval status require separate evidence.
CAPSULE, HARD
View registry recordThe registry names these ingredients. The formulation’s exact chemical form has not been confirmed.
PROGRAF 1 mg capsule
Named ingredient: Tacrolimus
View registry recordRegistry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Oslo Universitetssykehus HF
Oslo, 0372, Norway
Anders Åsberg
First Submitted
June 10, 2026
Download the complete CTIS (EMA) record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: European Medicines Agency (EMA), Clinical Trials Information System (CTIS). Original record and public documents are available on CTIS.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved:
TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic
Contact the study team to confirm eligibility.